All In Biotech

Drug Trial Radar · NCT05347693

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge in Participants With Chronic Kidney Disease Treated for Hyperkalaemia

Last checked: Nov 20, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Mar 24, 2022

Primary completion

Dec 10, 2024

Study completion Dec 10, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital. The study will compare SZC to standard of care (SoC) with the goal of determining: * If continued use of SZC maintains normokalaemia (NK) better than SoC after participant discharge from the hospital. * If continued use of SZC after discharge will reduce HK related healthcare resource utilisation compared to SoC.

Conditions

  • Hyperkalaemia
  • Chronic Kidney Disease

Interventions

  • Sodium Zirconium Cyclosilicate (SZC)Drug

    White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement. Label text will be translated into local language.

  • Local standard of careDrug

    Local SoC in the country to be used as per local label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence (Yes/No) of NK (K+ Between 3.5 and 5.0 mmol/L, Inclusive) at 180 Days Post-dischargeTime frame: At 180 days post-discharge (Visit 10)

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Bonheiden, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Annonay, France

  • Research Site

    Ars-Laquenexy, France

  • Research Site

    Nice, France

  • Research Site

    Saint-Priest-en-Jarez, France

  • Research Site

    Bari, Italy

  • Research Site

    Foggia, Italy

  • Research Site

    Parma, Italy

  • Research Site

    Pavia, Italy

  • Research Site

    Eindhoven, Netherlands

  • Research Site

    Algeciras, Spain

  • Research Site

    Almería, Spain

  • Research Site

    Badajoz, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Burgos, Spain

  • Research Site

    Getafe, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Salamanca, Spain

  • Research Site

    San Sebastián de los Reyes, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Talavera de la Reina, Spain

  • Research Site

    Zamora, Spain

  • Research Site

    Doncaster, United Kingdom

  • Research Site

    Hull, United Kingdom

  • Research Site

    Salford, United Kingdom

  • Research Site

    Stevenage, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.